Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer

Gregor Seliger, Lutz P. Mueller, Thomas Kegel, Eva J. Kantelhardt, Axel Grothey, Regina Große, Hans Georg Strauss, Heinz KoelbL., Christoph Thomssen, Hans Joachim SchmolL.

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background: This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxelpretreated epithelial ovarian cancer. Patients and Methods: Heavily pretreated patients (N = 30; median age, 61 years) received docetaxel, 55 mg/m2; gemcitabine, 500 mg/m2 (day 1); and oxaliplatin, 70 mg/m2 (day 2) biweekly. Twelve patients had platinum-sensitive disease, and 18 patients had platinum-resistant disease. Results: Median follow-up was 18.6 months. No differences in patient characteristics were observed between patients with carboplatinum-sensitive and carboplatinum-resistant disease. In patients with carboplatin-sensitive disease, an overall response (OR) of 83.3%, a progression-free survival of 10.6 months, and an overall survival of 18.9 months were observed. In patients with carboplatinum-resistant disease, an OR was seen in 38.9% with a progression-free survival of 5.3 months and an overall survival of 16.3 months. Patients with platinum-refractory disease (progression under previous carboplatinum therapy, n = 13) had an OR of 23%, whereas patients with objective response but relapse less than 6 months after carboplatinum therapy had an OR of 80.0%. Grade 3 and 4 toxicities were only observed for anemia (6.7%), neutropenia (20.0%), thrombopenia, peripheral neuropathy, and diarrhea (16.7%). No neutropenic fever or treatment-related death occurred. Conclusions: In comparison with current standard protocols, a combination of docetaxel, gemcitabine, and oxaliplatin showed considerably higher efficacy without remarkable increased toxicity; particularly for patients with early relapse after a platinum-containing therapy.

Original languageEnglish (US)
Pages (from-to)1446-1453
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume19
Issue number8
DOIs
StatePublished - Nov 1 2009

Keywords

  • Docetaxel
  • Gemcitabine
  • Ovarian cancer
  • Oxaliplatin
  • Platinum-refractory

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Seliger, G., Mueller, L. P., Kegel, T., Kantelhardt, E. J., Grothey, A., Große, R., Strauss, H. G., KoelbL., H., Thomssen, C., & SchmolL., H. J. (2009). Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. International Journal of Gynecological Cancer, 19(8), 1446-1453. https://doi.org/10.1111/IGC.0b013e3181b62f38